Business Development
The Business Development team at Access Pharmaceuticals is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for our main products MuGard™ and ProLindac™, as well as for our Cobalamin™ oral drug delivery and disease targeting technologies.
MuGard™ is our approved product for oral mucositis. We are looking for commercial partners in North America and the Far East.
ProLindac™ is our major chemotherapeutic compound, currently in Phase 2 clinical development.
We are open to discussing arrangements of all types. To learn more about our products and capabilities please contact Phillip Wise by sending an email to the address below.